Human Organ Chip Systems Reshape Drug Development

Human organ chips are emerging as human-relevant testbeds for drug discovery and disease modeling, led by Donald Ingber’s team at Harvard’s Wyss Institute.

The FDA and NIH are becoming more supportive of non-animal approaches, signaling a shift away from exclusive reliance on animal data.

Despite strong promise, adoption in pharma remains slow because the systems are costly, low-throughput, and require new technical expertise.

Studies suggest organ chips could save money by replacing some toxicity tests and reducing late-stage drug failures.

If widely used, they could shorten development timelines, cut R&D costs, and improve safety and patient matching.